Présentation des résultats financiers du 1er semestre 2021 d’Inventiva
September 10, 2021 09:00 ET
|
INVENTIVA
Daix (France), le 10 septembre 2021 – Inventiva (Euronext Paris et Nasdaq : IVA), société biopharmaceutique spécialisée dans le développement clinique de petites molécules administrées par voie orale...
Inventiva’s 2021 First-Half Financial Results Presentation
September 10, 2021 09:00 ET
|
INVENTIVA
Daix (France), September 10, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment...
Global Cancer Stem Cells Market to Surpass $1,898.3 Million, Growing with a CAGR of 11.8% from 2019 to 2026, Post-COVID-19 Disaster by Research Dive
August 17, 2021 09:02 ET
|
Research Dive
New York, USA, Aug. 17, 2021 (GLOBE NEWSWIRE) -- A newest report on the global cancer stem cells market has been added by Research Dive to its repository. The report presents exhaustive insights on...
Global Cancer Stem Cells Market to Witness Exponential Growth Owing to the Rising Efficiency of Stem Cell Therapy – Informative Report [180 Pages] by Research Dive
August 02, 2021 09:00 ET
|
Research Dive
New York, USA, Aug. 02, 2021 (GLOBE NEWSWIRE) -- A recently published report by Research Dive states that the global cancer stem cells market is expected to witness a rise in revenue from $786.3...
Global Liver Institute Offering Multilingual Materials and Grants for International NASH Day on June 10
March 04, 2021 09:24 ET
|
Global Liver Institute
Washington, DC, March 04, 2021 (GLOBE NEWSWIRE) -- Global Liver Institute (GLI) is pleased to announce that the 2021 International NASH Day (#NASHday) will be held on June 10, 2021, with the theme,...
Surrozen Awarded NIH Grant to Support Development of SZN-043, a Liver-Specific Regenerative Antibody, for the Treatment of Severe Alcoholic Hepatitis
October 15, 2020 07:00 ET
|
Surrozen, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies, has been awarded an NIH grant to...
89bio Announces Positive Topline Results from its Phase 1b/2a Trial of BIO89-100 in NASH
September 14, 2020 07:01 ET
|
89bio, Inc.
All dose groups achieved statistically significant reductions in liver fat, with relative reductions of up to 60% versus baseline and up to 70% versus placebo Favorable safety and...
89bio Announces Proposed Public Offering of Common Stock
July 06, 2020 06:30 ET
|
89bio, Inc.
SAN FRANCISCO, July 06, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
Surrozen Announces Publication of Two Abstracts Providing Evidence for Liver-Targeted Tissue Regeneration
May 04, 2020 10:00 ET
|
Surrozen, Inc.
-- Abstracts originally accepted for 2020 Digestive Disease Week Conference – to be published online -- SOUTH SAN FRANCISCO, Calif., May 04, 2020 (GLOBE NEWSWIRE) -- Surrozen Inc., a...
89bio Announces Closing of Enrollment in its Phase 1b/2a NASH Trial and Reports New Preclinical Data Confirming BIO89-100’s Mechanism of Action Via Potent FGF Receptor Agonism
April 13, 2020 08:30 ET
|
89bio, Inc.
- Closed enrollment in its Phase 1b/2a NASH trial with 98% of patients enrolled and delays initiation of its SHTG trial due to the COVID-19 pandemic; Reaffirms guidance for NASH trial topline data in...